Revlimid (lenalidomide) – Risk of second primary malignancies in authorised indication Revlimid (lenalidomide) is an immunomodulating agent first licensed via a European assessment procedure in 2007, subject to a number of risk minimisation measures including a pregnancy prevention plan to ensure its safe use. Structurally related to thalidomide, Revlimid is authorised for use in combination [...]
Aliskiren – New contraindications and warnings due to the risks of cardiovascular and renal adverse reactions (Brands include Rasilez, Rasilez HCT, Rasilamlo) Aliskiren is an antihypertensive agent which inhibits the renin-angiotensin-aldosterone system through a direct effect on renin, blocking the conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin II. [...]
Suggested treatment algorithm for patients with metastatic neuroendocrine tumours Reference: Öberg KE. Management of neuroendocrine tumours: Current and future therapies. Expert Rev Endocrinol Metab. 2011;6(1):49-62. [adapted]. MIMS Ireland Copyright®
Table 1 - Histological classification of neuroendocrine tumours (NET)1,3 Differentiation Grade Meta-stases Mitotic Count Ki-67 index (%) Traditional Classification ENETS, WHO Classification Tumour size (cm) Well differentiated Low grade (G1), Benign -a ±b < 2 per 10 HPF ≤ 2 Carcinoid, islet cell, pancreatic NET Neuroendocrine tumour, grade 1 ≤1 Intermediate grade (G2), Low malignancy ± [...]
Evolving Strategies for the Management of Neuroendocrine tumours1,2,3 Neuroendocrine tumours (NETs) are a genetically diverse group of malignant solid tumours arising from neuroendocrine cells throughout the body (including in the thymus, lung, pancreas, GI tract and less common sites). They can be either clinically symptomatic (i.e., ‘functioning’), producing peptides causing characteristic hormonal syndromes, or silent, [...]
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Atorvastatin 10mg, 20mg, 40mg, 80mg. Description: Yellow, biconvex film-coated tablets marked HLA10, HLA20, HLA40 or HLA80 respectively. 10mg, 20mg, 40mg: Round. 80mg: Oval. Presentation: 10mg-28, €14.66; 20mg-28, €27.51; 40mg-28, €28.30; 80mg-28, €32.50. Indications: Adjunct to diet in primary hypercholesterolaemia (HC), heterozygous familial HC or [...]
Company: Dexcel Pharma Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Atorvastatin 10mg, 20mg, 40mg. Description: White round film-coated tablets marked 10, 20 or 40 on one side respectively. Presentation: 10mg-28, €14.66; 20mg-28, €27.51; 40mg-28, €28.30. Indications: Adjunct to diet in primary hypercholesterolaemia (HC), heterozygous familial HC or mixed hyperlipidaemia. Homozygous familial HC (as [...]
Company: Pfizer Healthcare Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Atorvastatin 10mg, 20mg, 40mg, 80mg. Description: White round film-coated tablets marked ATV on one side and 10, 20, 40 or 80 on reverse respectively. Presentation: 10mg-30, €15.60; 20mg-30, €29.40; 40mg-30, €30.30; 80mg-30, €34.80. Indications: Adjunct to diet in primary hypercholesterolaemia (HC), heterozygous familial [...]
Company: Clonmel Healthcare Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Candesartan cilexetil 4mg, 8mg, 16mg. Description: White biconvex tablets scored and marked C4, C8 or C16 respectively. Can be divided into equal halves. Presentation: 4mg-28, €13.60; 8mg-28, €17.29; 16mg-28, €23.34. Indications: Essential hypertension. Treatment of patients with heart failure and left ventricle systolic [...]
Company: Clonmel Healthcare Ltd. Legal category: Prescription. GMS. Sport prohibited. Active ingredients: Candesartan cilexetil/hydrochlorothiazide 16mg/12.5mg. Description: White biconvex tablets scored and marked CH16. Presentation: 16mg/12.5mg-28, €23.34. Indication: Essential hypertension, where monotherapy with candesartan cilexetil or hydrocholorothiazide (HCTZ) is not sufficient. Pharmacology: Candesartan is an angiotensin II receptor antagonist, selective for AT1 receptors, with tight binding [...]
Loading ...
